ALT5 Sigma Sees Unusually High Options Volume (NASDAQ:ALTS)

ALT5 Sigma Corporation (NASDAQ:ALTS) saw unusually large options trading activity on Wednesday. Stock investors acquired 7,349 call options on the company. This is an increase of 53% compared to the average volume of 4,815 call options.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ALT5 Sigma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Trading of ALT5 Sigma

A number of hedge funds have recently modified their holdings of the stock. Evernest Financial Advisors LLC acquired a new position in ALT5 Sigma during the 2nd quarter worth approximately $87,000. Shay Capital LLC purchased a new stake in ALT5 Sigma in the 3rd quarter valued at approximately $133,000. Two Sigma Investments LP acquired a new stake in shares of ALT5 Sigma during the third quarter valued at $1,827,000. Jump Financial LLC purchased a new position in shares of ALT5 Sigma during the 3rd quarter worth $2,690,000. Finally, UBS Group AG boosted its holdings in shares of ALT5 Sigma by 1,769.3% in the 3rd quarter. UBS Group AG now owns 681,877 shares of the company’s stock valued at $1,834,000 after purchasing an additional 645,399 shares during the last quarter. Hedge funds and other institutional investors own 6.27% of the company’s stock.

ALT5 Sigma Stock Up 30.7%

NASDAQ ALTS traded up $0.56 during trading hours on Wednesday, reaching $2.37. The company’s stock had a trading volume of 9,622,263 shares, compared to its average volume of 4,885,166. The firm’s 50-day moving average price is $1.59 and its 200-day moving average price is $3.85. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 1.45. ALT5 Sigma has a 1 year low of $1.08 and a 1 year high of $10.95.

ALT5 Sigma (NASDAQ:ALTS) last released its quarterly earnings results on Monday, January 12th. The company reported $0.29 earnings per share for the quarter. ALT5 Sigma had a negative return on equity of 179.27% and a negative net margin of 74.89%.The company had revenue of $7.58 million for the quarter.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.